R

Rhythm Pharmaceuticals
D

RYTM

87.820
USD
-2.32
(-2.57%)
Market Closed
Volume
9,289
EPS
-3
Div Yield
-
P/E
-28
Market Cap
6,018,533,547
Overview
Related Instruments
A
ACAD
21.095 USD
-0.210
(-0.99%)
ALNY
ALNY
297.36 USD
-3.22
(-1.07%)
A
ARWR
74.910 USD
-0.620
(-0.82%)
BIIB
BIIB
193.860 USD
4.240
(2.24%)
BMY
BMY
59.460 USD
-0.070
(-0.12%)
E
ESPR
3.12500 USD
-0.00500
(-0.16%)
IONS
IONS
75.600 USD
-0.180
(-0.24%)
S
SRPT
16.805 USD
-0.165
(-0.97%)
VRTX
VRTX
434.27 USD
0.56
(0.13%)
More

Title: Rhythm Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.